SRR8942985
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.460
- MYC_TARGETS_V1+0.450
- E2F_TARGETS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.350
- G2M_CHECKPOINT+0.340
- TNFA_SIGNALING_VIA_NFKB+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- ALLOGRAFT_REJECTION+0.220
- MTORC1_SIGNALING+0.210
Top 10 suppressed
- HEME_METABOLISM-0.330
- P53_PATHWAY-0.300
- BILE_ACID_METABOLISM-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- PROTEIN_SECRETION-0.280
- NOTCH_SIGNALING-0.270
- APICAL_JUNCTION-0.230
- CHOLESTEROL_HOMEOSTASIS-0.190
- ESTROGEN_RESPONSE_LATE-0.160
- COAGULATION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-6546-01A-11R-1820-07 | — | cohortMD1 | 0.787 |
| 2 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.716 |
| 3 | SRR23036890 | — | — | 0.696 |
| 4 | SJEPD032407_D2.RNA-Seq | EPN | Anaplastic EPN | 0.688 |
| 5 | MDT-AP-3283 | Med | Medulloblastoma | 0.684 |
| 6 | MNG156 | — | — | 0.680 |
| 7 | SRR8518152 | — | E | 0.680 |
| 8 | TCGA-85-8276-01A-11R-2296-07 | — | cohortSQ1 | 0.677 |
| 9 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.675 |
| 10 | 3e94d9d5-8c59-4366-babb-193bdc57d661 | — | — | 0.673 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |